• Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Press release

ChemoTech's Proposed Strategic Changes Accepted by Nasdaq First North

Scandinavian ChemoTech

Scandinavian ChemoTech AB (publ) (the "Company") today announces that, based on information disclosed in the Company's press releases published on Tuesday, March 31, ahead of the notice of the Annual General Meeting, Nasdaq Stockholm has communicated its preliminary assessment regarding the Company's proposed strategic changes.

 

Nasdaq Stockholm shares the Company's assessment that the strategic change, as proposed, does not constitute such a fundamental change in operations as referred to in item 2.5.1 of the Nasdaq First North Growth Market Rulebook.

 

Nasdaq Stockholm has, however, emphasized that it reserves the right to revise this assessment should circumstances change.

 

"We are pleased that Nasdaq shares our assessment regarding the proposed changes and that the AGM will be able to decide in May," says Mohan Frick, CEO and Co-founder.